Reviewer’s report

Title: Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials

Version: 0 Date: 20 Oct 2016

Reviewer: Nilay Kumar

Reviewer's report:

I have read with interest the systematic review and meta analysis by Qi et al where the authors studied the safety and efficacy of Ramosetron in patients with diarrhea predominant IBS.

1. Introduction may be shortened. Lines 2,3,4 on page 5 can be removed from the introduction.

2. Since most outcomes are subjective and were likely measured on an ordinal scale i.e. relief of abdominal discomfort, diarrhea etc. and were analyzed as dichotomous outcomes in the meta analysis, the authors should clarify whether definitions for symptom relief were consistent across studies. Were subjective outcomes measured using standardized/validated tools in different studies? If not, the authors should discuss how this could impact interpretation of their study findings in the limitations section of the paper.

3. The authors present a subgroup analysis of outcomes according to sex. Was there an interaction of sex with treatment allocation for safety and efficacy outcomes?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organisation that holds or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

No competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal